Drug intelligence / Profile preview

QLM1016

Development stage: Phase 3
Lead developer: Qilu Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

QLM1016 is a small molecule investigational drug developed by Qilu Pharmaceutical for the treatment of schizophrenia. It is currently in Phase 3 clinical trials, where its antipsychotic efficacy and safety are being evaluated in adult patients diagnosed with schizophrenia. The precise mechanism of action for QLM1016 has not been disclosed and remains unknown. The drug is administered orally and, as of now, has not received regulatory approval in any country[1][4][5].

Beyond the preview

Go deeper on QLM1016.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QLM1016.

Explore the full profile